We demonstrated that the growth inhibitory effect of mifepristone on ovarian cancer cells was associated with inhibition of DNA synthesis, down-regulation of transcription factor E2F1 needed for S phase progression, and inhibition of the activity of cell cycle regulatory kinase, cyclin dependent kinase 2 (Cdk2). The gene discussed is CDK2; the disease is ovarian carcinoma.